OKYO Pharma Beheer

Beheer criteriumcontroles 3/4

De CEO OKYO Pharma is Gary Jacob, benoemd in Jan2021, heeft een ambtstermijn van 3.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.11M, bestaande uit 35.2% salaris en 64.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.14% van de aandelen van het bedrijf, ter waarde $ 48.18K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 3.4 jaar.

Belangrijke informatie

Gary Jacob

Algemeen directeur

US$1.1m

Totale compensatie

Percentage CEO-salaris	35.2%
Dienstverband CEO	3.8yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	3.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Gary Jacob's beloning veranderd ten opzichte van OKYO Pharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	US$1m	US$392k	-US$17m
Mar 31 2023	US$1m	US$433k	-US$13m
Dec 31 2022	n/a	n/a	-US$11m
Sep 30 2022	n/a	n/a	-US$7m
Jun 30 2022	n/a	n/a	-US$6m
Mar 31 2022	US$2m	US$350k	-US$5m
Dec 31 2021	n/a	n/a	-US$5m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	-US$4m
Mar 31 2021	US$872k	US$85k	-US$3m

Compensatie versus markt: De totale vergoeding ($USD 1.11M ) Gary } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Gary is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Gary Jacob (77 yo)

3.8yrs

Tenure

US$1,114,000

Compensatie

Dr. Gary S. Jacob, PhD, served as an Independent Director at Virpax Pharmaceuticals, Inc. since April 2020 until July 25, 2022. He had been an Independent Director of Cardiff Oncology, Inc. since February...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gary Jacob	CEO & Executive Director	3.8yrs	US$1.11m	0.14% $ 48.2k
Michael Beck	Founder	no data	geen gegevens	geen gegevens
Keeren Shah	Chief Financial Officer	4.3yrs	geen gegevens	geen gegevens
Rajkumar Patil	Chief Scientific Officer	3.7yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van OKYO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gary Jacob	CEO & Executive Director	3.8yrs	US$1.11m	0.14% $ 48.2k
Bernard Denoyer	Independent Non-Executive Director	2.9yrs	US$51.00k	0% $ 0
Gabriele Marco Cerrone	Non-Executive Chairman	3.8yrs	US$1.31m	29.12% $ 10.3m
John Brancaccio	Independent Non-Executive Director	4.4yrs	US$86.00k	0.025% $ 9.0k
Jay Pepose	Member of Scientific Advisory Board	1.8yrs	geen gegevens	geen gegevens
Willy Simon	Senior Independent Non-Executive Director	9yrs	US$50.00k	0.026% $ 9.4k
Napoleone Ferrara	Member of Scientific Advisory Board	4.3yrs	geen gegevens	geen gegevens
Pedram Hamrah	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Victor Perez	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Anat Galor	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Mark Milner	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

73yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van OKYO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

OKYO Pharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer, Effective September 1, 2023

OKYO Pharma Limited, Annual General Meeting, Sep 07, 2022

OKYO Pharma Limited Appoints Gary S. Jacob as Chief Executive Officer

Recent updates

OKYO Pharma Limited Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $4 million.

Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $1.6389 million.

Okyo Pharma Limited Announces Filing of an Investigational New Drug (Ind) Application for Ok-101 to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (DED)

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Plans to Initiate Phase 2 Trial of Ok-101 in Neuropathic Corneal Pain

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer, Effective September 1, 2023

New minor risk - Shareholder dilution

OKYO Pharma Limited Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular Ok-101 for Dry Eye Disease

OKYO Pharma's Ordinary Shares of No Par Value, Fully Paid Cancels from Admission to Trading on London Stock Exchange

OKYO Pharma Announces Change of Delisting Date to 22 May 2023

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

OKYO Pharma Limited Announces U.S. IND Filing on Ok-101 for the Treatment of Dry Eye Disease

OKYO Pharma Plans Fourth Quarter 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

OKYO Pharma Limited, Annual General Meeting, Sep 07, 2022

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Limited Announces Successful Completion of A Pre-IND Meeting with the U.S. Food and Drug Administration on the Development of OK-101 to Treat Dry Eye Disease

OKYO Pharma Limited Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease

OKYO Pharma Announces Positive Data and Results in an Animal Model Using Topically Administered OK-201 to Treat Neuropathic Ocular Pain

OKYO Pharma Limited Has U.S. Patent Issues Covering its Lipid Conjugated Peptide Analogues for Treating Ocular Pain and Inflammation

Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS

OKYO Pharma Limited Appoints Gary S. Jacob as Chief Executive Officer

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd